BB Adamant Medtech & Services (Lux)
Medtech & Services is an investment in 10% of global gross domestic product: Healthcare sector excluding drugs
Bottom line: above-average and steady growth compared to the broad market
Focusing on profitable, liquid mid and large cap companies with an established product portfolio
Please find a more detailed description of share classes here.
The Fund invests worldwide in companies active in the medical technology and healthcare services sector. Stock selection is based on fundamental company analysis, focusing in particular on the medical benefits and the potential savings for the healthcare system as well as the expected market potential of a company’s products and services.
Indexed performance (as at: 26.10.2021)
NAV: USD 556.60 (25.10.2021)
Rolling performance (25.10.2021)
|25.10.2020 - 25.10.2021||20.22%||22.45%|
|25.10.2019 - 25.10.2020||21.54%||27.83%|
|25.10.2018 - 25.10.2019||10.70%||18.86%|
|25.10.2017 - 25.10.2018||16.69%||14.25%|
Annualized performance (25.10.2021)
|Since Inception p.a.||13.14%||16.41%|
Cumulative performance (25.10.2021)
Facts & Key figures
The Fund invests worldwide in companies active in the medical technology and healthcare services sector. Aim is to provide investors an attractive Healthcare Fund solution by investing in the entire healthcare universe with the exclusion of drug makers. Experienced sector specialists focus on profitable, liquid mid- and large-cap companies with an established product portfolio as well as fast growing small-cap companies with leading-edge technology offering. Stock selection is based on fundamental company analysis, focusing in particular on the medical benefits and the potential savings for the healthcare system as well as the expected market potential of a company’s products and services. A global network of experts spanning scientific and industrial fields supports the Management Team in forming opinions and making investment decisions. The selection of the portfolio companies is entirely bottom-up, independent of benchmark weightings.Show moreShow less
Investment suitability & Risk
|Investment Manager||Bellevue Asset Management AG|
|Custodian||RBC Investor Services, Luxembourg|
|Fund Administrator||RBC Investor Services, Luxembourg|
|Year end closing||30. Jun|
|NAV Calculation||Daily "Forward Pricing"|
|Cut of time||15:00 CET|
|Subscription Fee (max.)||5.00%|
|Total expense ratio (TER)||2.21% (30.09.2021)|
|Legal form||SICAV Luxembourg jurisdiction|
|SFDR category||Article 8|
Key data (30.09.2021, base currency EUR)
|No. of positions||57|
Top 10 positions
Breakdown by sector
Opportunities & Risks
- Digitalization of the healthcare sector is boosting medtech companies’ growth and earnings.
- Focusing on profitable, liquid mid and large cap companies with an established product portfolio as well as on rapidly growing small cap businesses delivering cuttingedge technology.
- Managed care profits from the privatization of the health insurance sector and lower treatment costs.
- Minimally invasive techniques gaining ground – shorter treatment times reduce healthcare costs.
- Bellevue – Healthcare pioneer since 1993 and today one of the biggest independent investors in the sector in Europe.
- Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- The fund invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The fund may invest in financial instruments that might have a relatively low level of liquidity, which can in turn affect the fund’s liquidity.
- Investing in emerging markets entails the additional risk of political and social instability.
- Increased opportunities through possible derivative transactions go hand in hand with increased risk of losses.
Review / Outlook
September was a month of negative returns as global stocks (MSCI World Net -2.2%), the Euro Stoxx 50 (-3.4%) and Germany’s Dax index (-3.6%) all headed south. Macro factors, such as rising US bond yields and uncertainties in China, were mostly to blame for the stock market weakness. The medtech sector (MSCI World Healthcare Equipment & Supplies (-2.6%) and the BB Adamant Medtech & Services Fund (-2.3%) were unable to escape the general sell-off either. There have also been signs of rising input costs, supply chain challenges and labor shortages in the healthcare sector, but, generally speaking, these factors have had a much milder impact compared to what other sectors are experiencing.
Baxter (+8.0%) and Avantor (+5.8%) delivered positive returns. Both announced major acquisitions. Baxter issued a bid for Hill-Rom, a manufacturer of hospital beds, for USD 11.7 bn, while Avantor is taking over supplier Masterflex (bioprocessing) for USD 2.7 bn. Thermo Fisher Scientific's shares (+5.1%) rose after management presented a significantly stronger growth forecast at its Capital Markets Day. Diabetes specialists Dexcom (+5.4%) and Tandem Diabetes Care (+8.6%) also made good gains. Dexcom expects that almost all type 1 diabetics will be using a continuous glucose monitoring device by 2025. This would also benefit Tandem Diabetes Care, an insulin pump manufacturer that offers the most advanced sensor-augmented insulin pump for automated insulin delivery.
Selling in September largely erased the gains that the growth stocks Axonics (-11.4%), Abiomed (-8.7%), Idexx (-5.8%), Align (-4.2%) and Intuitive Surgical (-3.7%) had made in the previous month. Innovative large cap medtech companies such as Abbott (-4.6%), Danaher (-4.1%) and Medtronic (-3.7%) also declined in the wake of the rotation toward value stocks.
US health insurers generally traced the broader market’s moves in September after their weak showing in the previous month, but their performance was mixed. Molina (+3.0%), Anthem (+1.7%) and Centene (+1.0%) advanced, while United Health (-3.9%), Cigna (-3.1%) and Humana (-1.9%) traded lower. Investors have been wary about the “double whammy” of extra costs due to COVID-19 and the resumption of postponed medical treatments, which is why US health insurers are trading at a significant discount of about 30% versus the total market. The publication of third-quarter results in October should eliminate much of this uncertainty. We expect the companies we cover to provide their initial guidance for the 2022 financial year and these forecasts should narrow their discount versus the market. All performance data is in EUR / B shares.
Even without a normalization of the coronavirus situation, the sector-specific structural growth factors such as rising life expectancy and high rates of innovation will sustain the medtech & services sector's above-average growth versus the overall economy and power its high rates of profit growth.
Vaccination rates in key medtech & services markets (North America, Europe and Japan) were still trending higher at the end of September. Between 68% and 81% of the population in major Western European countries have already received at least one dose of a coronavirus vaccine. In the US, 64% of the total population is vaccinated and in Japan 71%.
This is an important prerequisite for achieving herd immunity in these countries without a significant increase in hospitalizations. Vaccine booster shots and oral antiviral therapies, a recent development, will also be available to prevent and treat COVID-19 infections. The number of elective procedures should therefore continue to normalize during the course of 2021 and 2022.
The Medtech & Services Fund invests in the entire healthcare market except for the drug developers. As a fully adequate healthcare investment vehicle, the fund aims to generate a significantly higher return than a traditional healthcare fund but with a comparable risk profile. The medtech & services sector is one of the stock market's most defensive sectors with sustainable outperformance potential and that is one reason for the unqualified success of our investment strategy. This and the additional growth from non-emergency treatments that had to be postponed during the pandemic create attractive entry points for investors.
Past performance is not a reliable indicator of future results and can be misleading. As the sub-fund is denominated in a currency that may differ than an investor’s base currency, changes in the rate of exchange may have an adverse effect on prices and incomes. Performance is shown net of fees and expenses for the relevant share class over the reference period. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. Individual costs are not taken into account and would have a negative impact on the performance. With an investment amount of EUR 1,000 over an investment period of five years, the investment result in the first year would be reduced by the front-end load of up to EUR 50 (5%) as well as by additional individual custody charges. In subsequent years, the investment result would also be reduced by the individual custody account costs incurred. The reference benchmark of this class is used for performance comparison purposes only (dividend reinvested). No benchmark is directly identical to a sub-fund, thus the performance of a benchmark is not a reliable indicator of future performance of the sub-fund it is compared to. There can be no assurance that a return will be achieved or that a substantial loss of capital will not be incurred. All figures in base currency in %, calculated by the total return / BVI method.Show moreShow less